Adults aged 45 years or older with a BMI of 27 kg/m 2 or more, and established cardiovascular disease, but without diabetes, were randomly assigned to once-weekly subcutaneous semaglutide (target dose 2.4 mg) or placebo, in addition to standard cardiovascular care
Appetite Suppression: By reducing appetite and promoting feelings of fullness, semaglutide can help individuals adhere to a calorie-restricted diet more easily
Strongly alkaline conditions introduce a different problem, precipitation of copper hydroxide and, in phosphate buffers, of copper phosphate
PK/PD profiling: Investigating absorption, distribution, half-life, and exposureresponse relationships, including the impact of lipidation on duration of action